The centralized and public availability of molecular sequence and clinical trial data presents an opportunity to identify potentially valuable linkages across the bench-to-bedside "T1" translational barrier. In this study, we sought to leverage keyword metadata (Medical Subject Heading [MeSH] descriptors) to infer relationships between molecular sequences and clinical trials, as indexed by GenBank and ClinicalTrials.gov. The results of this feasibility study found that approximately 30% of sequences in GenBank could be linked to trials and over 90% of trials in ClinicalTrials.gov could be linked to sequences through MeSH descriptors. In a cursory evaluation, we were able to consistently identify meaningful linkages between molecular sequences and clinical trials. Based on our findings, there may be promise in subsequent studies aiming to identify linkages across the T1 translational barrier using existing large repositories.
INTRODUCTION
Core to the success of translational bioinformatics endeavors will be ability to link relevant information across the bench-to-bedside translational barrier ("T1"). Insights across this barrier inherently involve the linking of bench-based research data with relevant clinical information. To date, many studies that aim to bridge across the T1 translational barrier have focused on the study of de novo data. To this end, there have been limited explorations into the development of a semantic infrastructure for linking clinical trial data to relevant molecular data.
Clinical hypotheses can often involve the direct manipulation of genetic material (such as in animal models) or the development of targeted interventions that interact with a particular molecule. As clinical hypotheses are tested, putative successful interventions are incorporated into clinical trials. As publications describe the background and results of a clinical trial, they are often catalogued in centralized resources. For example, this may be especially important when considering the identification of molecules or molecular properties that may be relevant in the context of a particular combination of disease phenotypes. As interventions are assessed for their clinical efficacy and effectiveness, it may be imperative to identify linkages to underlying molecular mechanisms. Drawing correlations between bench and bedside research collectively comprise the "holy grail" for translational bioinformatics, yet this can be often hindered by limited availability of data sets that can be cross-linked. Previous work has explored the ability and challenges to navigating information resources (e.g., MedlinePlus, ClinicalTrials.gov, OMIM, and PubMed/MEDLINE) from phenotype to genotype to answer specific questions about genes and gene products related to specific diseases (e.g., "What genes cause the disease?" and "Are there gene therapies or clinical trials for this disease") [1] . Major challenges to linking or integration of these resources included data complexity, dynamic data, diverse foci and number of resources, and lack of standardized data and knowledge representation. Numerous efforts have emerged to address these data and knowledge integration issues in different contexts (e.g., translational research [2] and biology [3] ).
Both the molecular and clinical trial communities have embraced the use of centralized repositories [4] . Within the molecular biology community, almost all reference molecular sequence data are publicly available via GenBank (presently containing over 100 million records) [5] ; ClinicalTrials.gov is a publicly accessible resource that catalogues clinical trials (presently containing over 75 thousand records) [6, 7] . Both resources are maintained by the National Library of Medicine (NLM) (the former by the National Center for Biotechnology Information [NCBI] and the latter by the Lister Hill National Center for Biomedical Communications in collaboration with the Food and Drug Administration) and readily downloadable.
Many of the NLM/NCBI resources are cross-linked through the Entrez interface and are collectively searchable from a single interface or through the Entrez programming utilities (EUtilities) [8, 9] . For example, it is possible to identify both articles in PubMed/MEDLINE and molecular sequences in GenBank that are associated with a given topic. The strong relationship between GenBank and publications that are largely indexed in MEDLINE [10] can lead to inferred annotations of molecular sequence data. Recent work has shown how these Entrezbased relationships can lead to approaches to link molecular information to relevant literature (e.g., identify keyword descriptors that are associated with publications that are affiliated with a group of related molecular sequences) [11] . Within ClinicalTrials.gov, keyword descriptors are explicitly applied to entries. Additional keyword descriptors can also be inferred, as in the case with GenBank entries, through associated publications.
Keyword descriptors that are part of controlled vocabulary or ontological structures can be leveraged for linking putatively related data elements. Preliminary studies demonstrate the possibility of leveraging existing semantic infrastructures to link genotypic information (e.g., as captured in molecular databases) to phenotypic (e.g., as captured in stores of clinical data). For example, previous work has demonstrated how one might make use of the Unified Medical Language System (UMLS) to link clinical concepts primarily represented in the Systematized Nomenclature of Medicine (SNOMED) to genomic concepts represented in the Gene Ontology (GO) [12, 13] . Additional work has explored how the controlled vocabulary primarily associated with MEDLINE, the Medical Subject Headings (MeSH) [14] , can be used to link disparate resources (e.g., OMIM, UMLS Metathesaurus, and GenBank [15] ) or identify possibly linked concepts [16] . In contrast to specific domain terminologies, such as SNOMED or GO, MeSH is designed primarily as an indexing terminology to capture the breadth of biomedical science that is required to meet information needs associated with the PubMed/ MEDLINE interface. Thus, while lacking potential deeper levels of domain knowledge (as leveraged by other semantic mediated linkage systems [17, 18] ), MeSH provides a broad list of concepts that may provide some traction for linking relevant objects to each other across the translational spectrum. For example, through a series of MeSH based queries to PubMed/ MEDLINE, it is possible to identify relevant citations that are related to each other across the entire spectrum of translational bioinformatics.
Building on the premise that MeSH-based annotations can be used to link related concepts, this study explores the feasibility of linking molecular sequence and clinical trial data leveraging MeSH descriptors either directly associated with clinical trials or inferred from published literature (i.e., PubMed/MEDLINE).
MATERIALS AND METHODS
For this feasibility study, the overall approach involved three major phases: (1) collecting PubMed Identifiers (PMIDs) and MeSH descriptors from GenBank, ClinicalTrials.gov, and PubMED/MEDLINE; (2) charactering and filtering by MeSH descriptors; and, (3) identifying linkages between molecular sequences and clinical trials based on PMIDs and MeSH.
Data Collection
Literature references and MeSH descriptors associated with sequences in GenBank and studies in ClinicalTrials.gov were collected. Figure 1 depicts the approach for extracting this information from GenBank, ClinicalTrials.gov, and PubMed/MEDLINE. Each step in the overall process is further described in the following sections.
Molecular Sequences from
GenBank-Molecular sequence data represent a fundamental component in many bench research endeavors. GenBank is a centralized repository for cataloguing molecular sequence data [5] . Through partnerships via the International Nucleotide Sequence Database Collaboration (INSDC), GenBank data are globally synchronized with European (EMBL) and Asian (DDBJ) repositories, thus representing a complete collection of nearly all publicly available molecular sequence data. Associated with each sequence entry in GenBank is a detailed set of metadata elements, organized into general bibliographic metadata and "Feature Table" as defined by the INSDC. Included among the over 70 metadata elements are fields like "ACCESSION" representing the unique identifier for the sequence and "REFERENCE" for literature relevant to the sequence that includes "AUTHOR," "TITLE," "JOURNAL," and "PUBMED" conveying the citation and PMID. In a recent study, a significant portion (~30%) of GenBank records was found to be associated with PubMed/MEDLINE records through the PMIDs [11] . Preliminarily analyses have demonstrated the ability to leverage PMIDs to identify MeSH descriptors that are associated with a given GenBank record.
The entirety of GenBank is freely downloadable from NCBI [19] . A series of scripts was developed to extract and load GenBank metadata into a MySQL database thus enabling rapid query of GenBank records (e.g., "Which sequences have reference information?"). For sequences with references, E-Utilities was used to obtain the associated MeSH descriptors using the PMIDs (Figure 1.A) . This set of references and MeSH descriptors derived from information in GenBank was supplemented by information from PubMed/MEDLINE. Specifically, E-Utilities was used to query PubMed/MEDLINE directly to identify records containing information about molecular sequence data through the "Secondary Source ID" (SI) field (e.g., SI-GENBANK/AF306859) [20] ; MeSH descriptors were then obtained for the corresponding PMIDs (Figure 1 .B). The combined sets of PMIDs and MeSH descriptors will henceforth be referred to as GB/PMID and GB/P-MeSH respectively.
Clinical Trials from ClinicalTrials.gov-Clinical trials represent a primary means
for evaluating the safety and efficacy of new therapies and other interventions that have the potential for improving clinical practice. ClincialTrials.gov was developed in response to legislation mandating a comprehensive, publically accessible registry of federally and privately funded clinical trials [6, 7] . This Web-based registry maintains a common set of data elements for each trial including 40 major required and optional elements for descriptive information, recruitment information, location and contact information, administrative data, and optional supplementary information. Information about studies registered in ClinicalTrials.gov is viewable from the public Web site and can be downloaded as plain text or XML files from this site [21] . To facilitate registration of trial information from organizations, a Web-based data entry and management system called the Protocol Registration System was created [22, 23] .
Required elements associated with each registered study include study identifier, brief title, recruitment status, sponsor or funding source, eligibility criteria, study design, condition(s), and intervention(s). Optional elements may include investigators, references for background citations, references for completed studies, and keywords. The use of MeSH for conditions, interventions, and keywords is requested if possible; however, part of the data preparation phase of the registration process involves mapping to MeSH descriptors as needed and highlevel MeSH categories [6, 7] .
Based on a preliminary review of content within the XML files and Web pages for ClinicalTrials.gov, we observed that a combination of sources and methods would be needed to extract a more complete set of literature references and MeSH descriptors associated with each study. Table 1 Using the "Download Options" feature in ClinicalTrials.gov, the XML files for all full studies were downloaded. Each XML file was parsed according to the Document Type Definition (DTD)[24] to extract basic metadata (e.g., National Clinical Trials Identifiers [NCT ID] and title) and metadata associated with references. These references either represent literature that provide background for the study ("Background References") or report on results from the study ("Results References"). For either type of reference, the PMID, full citation, or both may be provided. In cases where a PMID was available, E-Utilities was used to retrieve associated MeSH descriptors. Similar to our GenBank analysis, E-Utilities was used to query PubMed/ MEDLINE to identify any additional references for clinical trials; these include references displayed on the ClinicalTrials.gov Web pages that are not in the corresponding XML file and are difficult to extract from the Web pages or any others that may be indicated by the "SI" field in PubMed/MEDLINE (e.g., SI-ClinicalTrials.gov/NCT00000419). MeSH descriptors associated with these records were similarly obtained for the corresponding PMIDs. The combined sets of PMIDs and MeSH descriptors will henceforth be referred to as CT/PMID and CT/P-MeSH respectively.
Finally, in examining the content displayed on the ClinicalTrials.gov public Web site for studies, we found that some information was not included in the XML files such as keywords, topic categories, and MeSH descriptors. To add these MeSH descriptors into the data set, we processed each Web page associated with a study to extract this information. This set of MeSH descriptors is referred to as CT/C-MeSH to represent MeSH descriptors obtained directly from ClinicalTrials.gov rather than through PubMed/MEDLINE; the set resulting from the combination of this set with CT/P-MeSH will be called CT/CP-MeSH.
Characterizing and Filtering by MeSH
An analysis of the four sets of MeSH descriptors collected for sequences in GenBank and studies in ClinicalTrials.gov (GB/P-MeSH, CT/P-MeSH, CT/C-MeSH, and CT/CP-MeSH) was performed to determine the distribution of descriptors across the 16 top-level MeSH 2009 categories. This analysis revealed that the hierarchies with the highest frequency based on the combined set of MeSH descriptors for clinical trials (CT/CP-MeSH) were "Diseases" (Category C) and "Chemicals and Drugs" (Category D). These two categories were used to filter each of the MeSH descriptor sets in order to use more focused and condensed sets to test the feasibility of linking molecular sequences and clinical trials through MeSH. In addition, due to the large size of GenBank, GB/P-MeSH was further filtered to include only the MeSH descriptors also occurring in the sets for clinical trials.
Linking Molecular Sequences and Clinical Trials
Based on the PMID and MeSH descriptor sets, two major types of linkages can be obtained: (1) links between sequences and trials through PMID and (2) Using the GB/PMID and CT/PMID sets, links between sequences and trials were identified based on common PMIDs. Three sets of linkages were identified between the MeSH descriptor set for sequences (GB/P-MeSH) and MeSH descriptor sets for trials (CT/C-MeSH, CT/PMeSH, and CT/CP-MeSH). Due to the potentially large number of and possibly irrelevant links, a score was calculated to measure the relevancy of each link based on the number of common MeSH descriptors between a given sequence and trial. In the case of links from trials to sequences, the general algorithm was as follows: (1) 
RESULTS

Molecular Sequences and Clinical Trials
GenBank (Release 172) An E-Utilities query to PubMed/MEDLINE performed on July 8, 2009 identified 3,790 articles with 3,397 associated NCT IDs representing studies in ClinicalTrials.gov. Combining these two sets resulted in 15,674 unique trials (20.94%) with 59,234 unique PMIDs (CT/PMID set). Table 2 depicts the breakdown of references by type (background or results) and source (ClinicalTrials.gov or PubMed/MEDLINE).
Using E-Utilities to query PubMed/MEDLINE, MeSH descriptors were obtained for each PMID in GB/PMID and CT/PMID to produce GB/P-MeSH and CT/P-MeSH, respectively. In addition, MeSH descriptors for each trial were extracted from the corresponding ClinicalTrials.gov Web pages to generate CT/C-MeSH. The CT/P-MeSH and CT/C-MeSH sets were then combined to create CT/CP-MeSH. Table 3 summarizes the number of unique sequences or trials, total number of MeSH descriptors, and total number of unique MeSH descriptors associated with each of these sets.
MeSH Hierarchy Characterization
The top-level hierarchy for each MeSH descriptor in GB/P-MeSH, CT/P-MeSH, CT/C-MeSH, and CT/CP-MeSH was identified. Table 4 and Figure 2 depict the distribution of descriptors across the sixteen hierarchies. The top three hierarchies were "Phenomena and Processes" (37.23%), "Organisms" (15.43%), and "Chemicals and Drugs" (12.63%) for GB/ P-MeSH; "Diseases" (53.80%), "Chemicals and Drugs" (41.15%), and "Psychiatry and Psychology" (3.40%) for CT/C-MeSH; "Analytical, Diagnostic and Therapeutic Techniques and Equipment" (20.02%), "Technology, Industry, Agriculture" (20.2%), and "Chemical and Drugs" (13.77%) for CT/P-MeSH; and, "Diseases" (31.48%), "Chemicals and Drugs" (26.74%), "Analytical, Diagnostic and Therapeutic Techniques and Equipment" (10.75%), and "Technology, Industry, Agriculture" (10.75%) for CT/CP-MeSH. The sets were subsequently filtered by "Diseases" and "Chemicals and Drugs" (the top two hierarchies based on CT/C-MeSH and CT/CP-MeSH) and GB/P-MeSH was further filtered to include descriptors only occurring in the clinical trials sets.
Molecular Sequence and Clinical Trial Linkages
Linking Molecular Sequences and Clinical Trials through PMID-The
PMIDs from GB/PMID and CT/PMID were used to identify links between molecular sequences and clinical trials. A total number of 78,259 links were identified involving 64,181 sequences and 426 trials. For a given sequence, the minimum number of links to trials was 1 and the maximum was 6; for a given trial, the number of links to sequences ranged from a minimum of 1 to a maximum of 41,152. Figure 3 depicts the sequences and literature references linked to the trial "Family Studies of Inherited Heart Disease" (NCT ID = NCT00001225) and Figure 4 lists the trials and literature references linked to the sequence "Homo sapiens Huntington's Disease (HD) mRNA, complete cds." (Accession ID = HUMHDA).
Linking Molecular Sequences and Clinical Trials through MeSH-Through
MeSH descriptors in the "Diseases" and "Chemicals and Drugs" hierarchies, three sets of linkages between sequences and trials were identified (Table 5) . Over 39 billion links were generated from GB/P-MeSH and CT/C-MeSH covering 90.41% of the trials, over 800 million were identified for CT/P-MeSH involving 18.72% of the total trials, and the combined set of CT/CP-MeSH resulted in almost 40 million links for 91.6% of the trials. The estimated upper bound for the number of sequences involved in each of these sets was about 35 million (30.00%).
For each link, the relevancy score was calculated based on the number of common MeSH descriptors to enable the ranking of sequences linked to a given trial. Figure 5 plots the distribution of sequences relative to trials based on the relevancy scores. CT/C-MeSH by itself was able to identify relevant sequences across all clinical trials. By contrast, CT/P-MeSH by itself does not offer as many significant sequences that are related to clinical trials. The combined set of MeSH descriptors (CT/CP-MeSH) was not dramatically affected by the CT/ P-MeSH; however, there were a number of instances where even if no CT/C-MeSH descriptors were available that CT/P-MeSH was able to facilitate the identification of relevant molecular sequences. As an example, Figure 6 presents MeSH descriptors and the MeSH-based links to sequences for the same trial in Figure 3. 
DISCUSSION
The development of approaches for identifying potential linkages across disparate data sources is essential towards the generation of putative testable hypotheses. Within the scope of translational bioinformatics, such hypotheses include those that aim to identify potentially related molecular sequences and clinical trials, thus transcending the "T1" bench-to-bedside translational barrier. In the present study, we were able to demonstrate the ability to link molecular sequences from GenBank to relevant clinical trials in ClinicalTrials.gov and vice versa. Using MeSH descriptors associated with GenBank records (through PubMed/ MEDLINE) and MeSH descriptors associated with ClinicalTrials.gov records (either directly, through PubMed/MEDLINE, or in combination), linkable molecular sequences and clinical trials can be identified.
The linkage between human-centric (e.g., ClinicalTrials.gov) and organism-agnostic (e.g., GenBank) resources presents an opportunity to identify putative model organisms for a given disease. We are currently working to develop an approach that leverages the results of the present study to discover potentially interesting organisms that may be associated with a clinical condition. In this feasibility study, the entirety of GenBank was considered to determine the feasibility of developing potentially meaningful linkages from ClinicalTrials.gov; however, the nature of sequences in GenBank is such that there are often numerous similar or even identical sequences. As a possible way to address this, we are planning to leverage curated molecular sequence resources such as RefSeq [25] or UniGene [26] . Additionally, we anticipate that the use of RefSeq or UniGene will help lead to a more statistically relevant understanding of the linkages between clinical trials and available molecular sequence data (by filtering out redundant sequences).
In this study, literature references associated with either GenBank or ClinicalTrials.gov were used as a surrogate for annotations. There is a keyword field in GenBank; however, it is not associated with a specific controlled vocabulary like MeSH. References in ClinicalTrials.gov are categorized as either "background" or "result" citations. In the present study, we treated these two references equivocally; however, it may be interesting to study the effect of using either of these category types exclusively compared with their combination. During our processing of ClinicalTrials.gov data, we observed that there were references that did not have a PMID (thus preventing an easy linkage to PubMed/MEDLINE). Future work could therefore involve reviewing these to determine why there is no PMID (e.g., abstract/poster or not indexed in PubMed/MEDLINE).
Because our approach to supplement the MeSH descriptors for both molecular sequences and clinical trials depended on PMIDs, a complete list of associated PMIDs was required for each sequence or trial. However, an interesting finding was that it was not possible to reliably get a complete list directly from either GenBank or ClinicalTrials.gov. For GenBank, previous work has characterized the types of discordance between which PMIDs are reported from GenBank compared with those that are in PubMed/MEDLINE [11] . Performing a similar type of analysis on ClinicalTrials.gov data reveals a similar trend (Figure 7 ). This further underscores the challenges in curating, maintaining, and synchronizing large repositories like GenBank, ClinicalTrials.gov, and PubMed/MEDLINE. Nonetheless, the infrastructure is in place for explicitly linking between key resources (e.g., PubMed/MEDLINE to GenBank or PubMed/ MEDLINE to ClinicalTrials.gov). Interestingly, a PubMed/MEDLINE search for records that are associated with both GenBank and ClinicalTrials.gov records (as recorded in the "Secondary Identifier" [SI] field) only retrieves two articles (PMID 16525138 and 16525137; query performed on August 31, 2009).
The present study focused on keyword metadata in the form of MeSH descriptors. Both GenBank and ClinicalTrials.gov have associated metadata fields that contain additional potentially valuable keyword terms that might be used to develop more reliable and complete linkages. For example, examination of the GenBank keyword field reveals that there are over 2 million terms (compared to the over 25,000 MeSH descriptors available). A possible future area of work may thus be to map these keywords to a hierarchy such as MeSH to get a more direct annotation of molecular sequence data as a comparison to those inferred by PubMed/ MEDLINE. With respect to ClinicalTrials.gov, other potential keywords (many of which might be directly derived from MeSH) include keywords provided by the sponsors or organizations (e.g., "Keywords provided by National Institutes of Health Clinical Center (CC)"), topic categories, conditions, and interventions. We have begun an analysis of these terms and have started identifying mechanisms to map them to MeSH descriptors (e.g., using natural language processing techniques). Finally, in considering PubMed/MEDLINE, we only focused on the use of MeSH descriptors. Next steps include making better use of MeSH qualifiers and substances to help identify additional linkages as well as help quantify the importance of linkages that are identified using solely MeSH.
One part of this study involved characterizing MeSH descriptors by identifying their corresponding hierarchies or categories in MeSH 2009. This characterization provided insights on the distribution of descriptors across MeSH hierarchies for molecular sequences compared with clinical trials and assisted in identifying an initial filtering strategy (i.e., by "Diseases" and "Chemicals and Drugs"). It is worth noting that in some cases a descriptor could not be found (e.g., may be from an earlier version of MeSH) and some descriptors fall into multiple hierarchies. Future work includes characterizing descriptors by semantic type or MeSH subhierarchies and exploring additional filtering strategies (e.g., including other hierarchies such as "Psychiatry and Psychology").
The initial approach of using PMIDs and MeSH descriptors to identifying potential relationships between sequences and trials revealed a vast number of linkages. Further evaluation of these linkages will be valuable for assessing their relevance and guiding the development of techniques for enhancing the ranking of results.
CONCLUSION
The ability to integrate disparate publicly available biomedical resources could be valuable for supporting and promoting research across the bench-to-bedside ("T1") translational barrier. In this study, we explored the feasibility of linking molecular sequences in GenBank and clinical trials in ClinicalTrials.gov leveraging literature from PubMed/MEDLINE and keyword metadata in the form of MeSH descriptors. The results obtained in this feasibility study indicate that this is a promising approach for identifying relevant linkages between sequences and trials. This study is associated with three articles (PMID 1975517, 2022018 , and 2144212). Links to four sequences were identified (A) where two articles were found to be common to the trial and sequences (B) and nine other articles associated with the sequences may be of interest (C). This sequence is associated with one article (PMID: 8458085). Links to three trials were identified (A) where one article was found to be common to the sequence and trials (B) and seventy-one other articles associated with the trials may be of interest (C). 
